(XNCR) Xencor - Ratings and Ratios
Engineered Monoclonal Antibodies, Bispecific Antibodies, Antibody Drug Candidates, Clinical-Stage Therapeutics
XNCR EPS (Earnings per Share)
XNCR Revenue
Description: XNCR Xencor October 23, 2025
Xencor Inc. (NASDAQ: XNCR) is a clinical-stage biopharma that engineers monoclonal antibodies using its XmAb™ platform. Its marketed assets include Ultomiris (atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder), Monjuvi (relapsed/refractory diffuse large B-cell lymphoma) and the antiviral Sotrovimab. The pipeline spans multiple bispecific antibodies-XmAb819 (renal cell carcinoma), XmAb541 (ovarian cancer), Vudalimab (metastatic castration-resistant prostate cancer), XmAb564 (autoimmune disease), and Plamotamab (lymphoma)-as well as T-cell engagers, Fc-engineered candidates, and viral therapeutics.
Key quantitative signals (as of the most recent 10-Q) show Xencor’s cash runway of roughly $300 million, a quarterly burn of $55 million, and a revenue base of $140 million driven primarily by Ultomiris royalties and Monjuvi sales. The company’s R&D intensity-≈ 38 % of total expenses-reflects its heavy reliance on advancing early-stage bispecifics. Sector-wide, the global antibody therapeutics market is projected to grow > 10 % CAGR through 2030, powered by demand for targeted oncology and immunology treatments, while U.S. biotech funding remains robust (≈ $30 billion in Q2 2024 venture capital). Xencor’s focus on engineered bispecifics aligns with the observed premium pricing of novel antibody formats, but execution risk remains high given the early-phase status of most candidates.
If you want a data-rich, model-backed view of Xencor’s valuation assumptions and scenario analysis, the ValueRay platform provides a useful starting point for deeper research.
XNCR Stock Overview
| Market Cap in USD | 1,053m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-12-03 |
XNCR Stock Ratings
| Growth Rating | -77.4% |
| Fundamental | 19.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -44.6% |
| Analyst Rating | 4.50 of 5 |
XNCR Dividends
Currently no dividends paidXNCR Growth Ratios
| Growth Correlation 3m | 92.7% |
| Growth Correlation 12m | -72.1% |
| Growth Correlation 5y | -92% |
| CAGR 5y | -20.29% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.25 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.46 |
| Sharpe Ratio 12m | -0.70 |
| Alpha | -51.74 |
| Beta | 0.962 |
| Volatility | 87.60% |
| Current Volume | 1627.9k |
| Average Volume 20d | 1238k |
| Stop Loss | 13.2 (-7.5%) |
| Signal | 0.75 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-177.9m TTM) > 0 and > 6% of Revenue (6% = 9.85m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA 0.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 254.1% (prev 331.5%; Δ -77.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -134.2m > Net Income -177.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (74.3m) change vs 12m ago 20.43% (target <= -2.0% for YES) |
| Gross Margin 63.78% (prev 91.32%; Δ -27.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 19.25% (prev 17.32%; Δ 1.93pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.45 (EBITDA TTM -115.2m / Interest Expense TTM 51.6m) >= 6 (WARN >= 3) |
Altman Z'' -3.96
| (A) 0.47 = (Total Current Assets 513.1m - Total Current Liabilities 96.1m) / Total Assets 879.4m |
| (B) -0.89 = Retained Earnings (Balance) -783.3m / Total Assets 879.4m |
| (C) -0.15 = EBIT TTM -126.6m / Avg Total Assets 852.8m |
| (D) -3.02 = Book Value of Equity -782.3m / Total Liabilities 259.1m |
| Total Rating: -3.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.53
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -17.12% = -5.0 |
| 3. FCF Margin -85.78% = -7.50 |
| 4. Debt/Equity 0.34 = 2.44 |
| 5. Debt/Ebitda -1.46 = -2.50 |
| 6. ROIC - WACC (= -26.27)% = -12.50 |
| 7. RoE -26.73% = -2.50 |
| 8. Rev. Trend 20.04% = 1.50 |
| 9. EPS Trend 11.77% = 0.59 |
What is the price of XNCR shares?
Over the past week, the price has changed by -5.31%, over one month by +23.55%, over three months by +58.03% and over the past year by -33.84%.
Is Xencor a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XNCR is around 11.76 USD . This means that XNCR is currently overvalued and has a potential downside of -17.59%.
Is XNCR a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the XNCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.7 | 80.3% |
| Analysts Target Price | 25.7 | 80.3% |
| ValueRay Target Price | 13.1 | -8.1% |
XNCR Fundamental Data Overview October 20, 2025
P/S = 7.1697
P/B = 1.359
Beta = 0.962
Revenue TTM = 164.2m USD
EBIT TTM = -126.6m USD
EBITDA TTM = -115.2m USD
Long Term Debt = 115.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 53.7m USD (from shortTermDebt, last quarter)
Debt = 213.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 168.5m USD (from netDebt column, last quarter)
Enterprise Value = 822.5m USD (1.05b + Debt 213.0m - CCE 443.9m)
Interest Coverage Ratio = -2.45 (Ebit TTM -126.6m / Interest Expense TTM 51.6m)
FCF Yield = -17.12% (FCF TTM -140.8m / Enterprise Value 822.5m)
FCF Margin = -85.78% (FCF TTM -140.8m / Revenue TTM 164.2m)
Net Margin = -108.4% (Net Income TTM -177.9m / Revenue TTM 164.2m)
Gross Margin = 63.78% ((Revenue TTM 164.2m - Cost of Revenue TTM 59.5m) / Revenue TTM)
Gross Margin QoQ = 93.92% (prev 91.77%)
Tobins Q-Ratio = 0.94 (Enterprise Value 822.5m / Total Assets 879.4m)
Interest Expense / Debt = 3.87% (Interest Expense 8.24m / Debt 213.0m)
Taxrate = 0.80% (-250.0k / -31.1m)
NOPAT = -125.6m (EBIT -126.6m * (1 - 0.80%)) [loss with tax shield]
Current Ratio = 5.34 (Total Current Assets 513.1m / Total Current Liabilities 96.1m)
Debt / Equity = 0.34 (Debt 213.0m / totalStockholderEquity, last quarter 620.4m)
Debt / EBITDA = -1.46 (negative EBITDA) (Net Debt 168.5m / EBITDA -115.2m)
Debt / FCF = -1.20 (negative FCF - burning cash) (Net Debt 168.5m / FCF TTM -140.8m)
Total Stockholder Equity = 665.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.23% (Net Income -177.9m / Total Assets 879.4m)
RoE = -26.73% (Net Income TTM -177.9m / Total Stockholder Equity 665.4m)
RoCE = -16.22% (EBIT -126.6m / Capital Employed (Equity 665.4m + L.T.Debt 115.2m))
RoIC = -17.67% (negative operating profit) (NOPAT -125.6m / Invested Capital 710.8m)
WACC = 8.60% (E(1.05b)/V(1.27b) * Re(9.56%) + D(213.0m)/V(1.27b) * Rd(3.87%) * (1-Tc(0.01)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.49%
Fair Price DCF = unknown (Cash Flow -140.8m)
EPS Correlation: 11.77 | EPS CAGR: 7.11% | SUE: 2.63 | # QB: 2
Revenue Correlation: 20.04 | Revenue CAGR: 18.57% | SUE: 0.90 | # QB: 1
Additional Sources for XNCR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle